{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:18:27Z","timestamp":1777508307860,"version":"3.51.4"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Most guidelines recommend rapid treatment initiation for patients with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection, but prospective US data are limited. The DIAMOND (NCT03227861) study using darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) 800\/150\/200\/10 mg is a phase 3 prospective study evaluating efficacy\/safety of a single-tablet regimen in a rapid-initiation model of care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adults aged \u226518 years began D\/C\/F\/TAF \u226414 days from diagnosis without screening\/baseline results; as results became available, participants not meeting predefined safety\/resistance stopping rules continued. Primary endpoint was virologic response (HIV-1 RNA &amp;lt;50 copies\/mL; intent-to-treat; US Food and Drug Administration [FDA] snapshot) at week 48; participant satisfaction was measured via the HIV Treatment Satisfaction Questionnaire status version (HIVTSQs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 109 participants, 87% were male, 32% black\/African American, median (range) age was 28 (range, 19\u201366) years, 25% of participants had HIV-1 RNA \u2265100 000 copies\/mL, 21% had CD4+ cell count &amp;lt;200 cells\/\u00b5L, and 31% enrolled \u226448 hours from diagnosis. At week 48, 97 (89%) participants completed the study and 92 (84%) achieved HIV-1 RNA &amp;lt;50 copies\/mL (FDA snapshot). There were no protocol-defined virologic failures; incidences of adverse events (AEs) and adverse drug reactions (33%) were low, no serious AEs were study drug related, and 1 (&amp;lt;1%) participant discontinued due to study drug related AE(s). The overall HIVTSQs score at week 48 was 58 (maximum: 60).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>At week 48, a high proportion of participants starting D\/C\/F\/TAF achieved HIV-1 RNA &amp;lt;50 copies\/mL and very few discontinued therapy. D\/C\/F\/TAF was well tolerated, no participants discontinued due to baseline resistance stopping criteria, and high treatment satisfaction among participants was recorded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT03227861.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz1213","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T20:09:21Z","timestamp":1577218161000},"page":"3110-3117","source":"Crossref","is-referenced-by-count":37,"title":["Darunavir\/Cobicistat\/Emtricitabine\/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study"],"prefix":"10.1093","volume":"71","author":[{"given":"Gregory D","family":"Huhn","sequence":"first","affiliation":[{"name":"Ruth M. Rothstein CORE Center, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Crofoot","sequence":"additional","affiliation":[{"name":"Crofoot Research Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moti","family":"Ramgopal","sequence":"additional","affiliation":[{"name":"Midway Immunology and Research Center, Fort Pierce, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Joseph","family":"Gathe","sequence":"additional","affiliation":[{"name":"Therapeutic Concepts, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Bolan","sequence":"additional","affiliation":[{"name":"Los Angeles LGBT Center, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghan","family":"Luo","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Titusville, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard Bruce","family":"Simonson","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E","family":"Nettles","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmela","family":"Benson","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Dunn","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,12,27]]},"reference":[{"key":"2021012201541298500_CIT0001","author":"Centers for Disease Control and Prevention.","year":"2019"},{"key":"2021012201541298500_CIT0002","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents.","year":"2019"},{"key":"2021012201541298500_CIT0003","volume-title":"Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy","author":"World Health Organization.","year":"2017"},{"key":"2021012201541298500_CIT0004","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society\u2013USA panel","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"2021012201541298500_CIT0005","doi-asserted-by":"crossref","first-page":"e1002015","DOI":"10.1371\/journal.pmed.1002015","article-title":"Initiating antiretroviral therapy for HIV at a patient\u2019s first clinic visit: the RapIT randomized controlled trial","volume":"13","author":"Rosen","year":"2016","journal-title":"PLoS Med"},{"key":"2021012201541298500_CIT0006","doi-asserted-by":"crossref","first-page":"e1002357","DOI":"10.1371\/journal.pmed.1002357","article-title":"Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: a randomized unblinded trial","volume":"14","author":"Koenig","year":"2017","journal-title":"PLoS Med"},{"key":"2021012201541298500_CIT0007","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jama.2018.1818","article-title":"Effect of offering same-day ART vs usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in Lesotho: the CASCADE randomized clinical trial","volume":"319","author":"Labhardt","year":"2018","journal-title":"JAMA"},{"key":"2021012201541298500_CIT0008","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0000000000002124","article-title":"RAPID ART: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population","volume":"33","author":"Coffey","year":"2018","journal-title":"AIDS"},{"key":"2021012201541298500_CIT0009","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/apc.2017.0309","article-title":"Linkage and antiretroviral therapy within 72 hours at a federally qualified health center in New Orleans","volume":"32","author":"Halperin","year":"2018","journal-title":"AIDS Patient Care STDS"},{"key":"2021012201541298500_CIT0010","doi-asserted-by":"crossref","first-page":"ofy104","DOI":"10.1093\/ofid\/ofy104","article-title":"Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the southern United States","volume":"5","author":"Colasanti","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2021012201541298500_CIT0011","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/QAD.0000000000001817","article-title":"A week-48 randomized phase-3 trial of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-naive HIV-1 patients","volume":"32","author":"Eron","year":"2018","journal-title":"AIDS"},{"key":"2021012201541298500_CIT0012","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/S2352-3018(17)30031-0","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study","volume":"4","author":"Orkin","year":"2017","journal-title":"Lancet HIV"},{"key":"2021012201541298500_CIT0013","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/15284336.2017.1387690","article-title":"HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies","volume":"18","author":"Lathouwers","year":"2017","journal-title":"HIV Clin Trials"},{"key":"2021012201541298500_CIT0014","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1097\/PHH.0000000000000025","article-title":"Engaging, recruiting, and retaining black men who have sex with men in research studies: don\u2019t underestimate the importance of staffing\u2013lessons learned from HPTN 061, the BROTHERS study","volume":"20","author":"Magnus","year":"2014","journal-title":"J Public Health Manag Pract"},{"key":"2021012201541298500_CIT0015","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1524-4733.2006.00121.x","article-title":"Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version","volume":"9","author":"Woodcock","year":"2006","journal-title":"Value Health"},{"key":"2021012201541298500_CIT0016","author":"Joint United National Programme on HIV\/AIDS.","year":"2014"},{"key":"2021012201541298500_CIT0017","article-title":"High level of preexisting NRTI resistance prior to switching to B\/F\/TAF: study 4030","author":"Acosta"},{"key":"2021012201541298500_CIT0018","article-title":"Long-term B\/F\/TAF switch efficacy in patients with archived preexisting resistance","author":"Andreatta"},{"key":"2021012201541298500_CIT0019","article-title":"Getting a jump on HIV: expedited ARV treatment at NYC sexual health clinics","author":"Blank"},{"key":"2021012201541298500_CIT0020","author":"Centers for Disease Control and Prevention.","year":"2019"},{"key":"2021012201541298500_CIT0021","author":"Centers for Disease Control and Prevention."},{"key":"2021012201541298500_CIT0022","article-title":"Age, gender, and race analyses of D\/C\/F\/TAF in HIV-1 treatment-na\u00efve patients","author":"Rashbaum"},{"key":"2021012201541298500_CIT0023","doi-asserted-by":"crossref","article-title":"Darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in HIV-1 treatment-na\u00efve patients: week 48 results in subgroups based on baseline viral load, CD4+ count, and WHO clinical staging","author":"Spinner","DOI":"10.1093\/ofid\/ofy210.550"},{"key":"2021012201541298500_CIT0024","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1089\/aid.2018.0100","article-title":"Prevalence of darunavir resistance in the United States from 2010 to 2017","volume":"34","author":"Brown","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2021012201541298500_CIT0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/phar.1728","article-title":"Impact of pill burden on adherence, risk of hospitalization, and viral suppression in patients with HIV infection and AIDS receiving antiretroviral therapy","volume":"36","author":"Scott Sutton","year":"2016","journal-title":"Pharmacotherapy"},{"key":"2021012201541298500_CIT0026","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12981-018-0204-0","article-title":"A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV","volume":"15","author":"Clay","year":"2018","journal-title":"AIDS Res Ther"},{"key":"2021012201541298500_CIT0027","article-title":"Progressive rises in weight and clinical obesity for TAF\/FTC+DTG and TDF\/FTC+DTG versus TDF\/FTC\/EFV: ADVANCE and NAMSAL trials","author":"Hill"},{"key":"2021012201541298500_CIT0028","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz\u2013based regimen for the treatment of HIV-1","volume":"381","author":"NAMSAL ANRS 12313 Study Group.","year":"2019","journal-title":"N Engl J Med"},{"key":"2021012201541298500_CIT0029","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","article-title":"Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"key":"2021012201541298500_CIT0030","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"2021012201541298500_CIT0031","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/QAI.0000000000001844","article-title":"Patient-reported outcomes in first-line antiretroviral therapy: results from NEAT001\/ANRS143 trial comparing darunavir\/ritonavir in combination with tenofovir\/emtricitabine or raltegravir","volume":"79","author":"George","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021012201541298500_CIT0032","article-title":"High levels of patient satisfaction and virologic suppression at 48 weeks in newly diagnosed black\/African American individuals rapidly initiating darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) in the DIAMOND study","author":"","year":"2019"},{"key":"2021012201541298500_CIT0033","doi-asserted-by":"crossref","article-title":"High rates of virologic suppression achieved in HIV-1\u2013infected adults rapidly starting antiretroviral therapy (ART) with the single-tablet regimen (STR) of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) 800\/150\/200\/10 mg regardless of baseline disease characteristics: week 48 subgroup analyses from the phase 3 DIAMOND trial","author":"Huhn","DOI":"10.1093\/ofid\/ofz359.046"},{"key":"2021012201541298500_CIT0034","author":"Prevention Access Campaign."},{"key":"2021012201541298500_CIT0035","author":"National Center for HIV\/AIDS Viral Hepatitis, STD, and TB Prevention, Division of HIV\/AIDS Prevention.","year":"2018"},{"key":"2021012201541298500_CIT0036","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jama.2018.21167","article-title":"HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable","volume":"321","author":"Eisinger","year":"2019","journal-title":"JAMA"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz1213\/32449487\/ciz1213.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/12\/3110\/35936423\/ciz1213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/12\/3110\/35936423\/ciz1213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T05:44:52Z","timestamp":1611380692000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/12\/3110\/5687816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,27]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,27]]},"published-print":{"date-parts":[[2020,12,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz1213","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,15]]},"published":{"date-parts":[[2019,12,27]]}}}